Magazine

Table: Lots of Headaches


AMBIEN HAND-OFF

Under the terms of its licensing deal, Pharmacia (PHA) must return the $902 million-selling sleep aid Ambien to its developer, Sanofi-Synth?labo, this spring. That leaves a big sales hole.

CELEBREX SLOWDOWN

Growth for the company's flagship $3.1 billion arthritis drug Celebrex slowed in 2001 after questions were raised about possible cardiovascular side effects.

FDA WOES

Last year, the Food & Drug Administration delayed approval of injectable painkiller parecoxib and glaucoma treatment Xalcom pending more data.

AGRICULTURAL DRAG

Monsanto's (MON) agribusiness unit has been hurt by resistance to genetically modified seeds. Pharmacia will spin off its remaining stake in the business this fall.


Monsanto vs. GMO Haters
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus